<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2604-1227</journal-id>
<journal-title><![CDATA[Revista mexicana de oftalmología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. oftalmol]]></abbrev-journal-title>
<issn>2604-1227</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oftalmología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2604-12272019000400194</article-id>
<article-id pub-id-type="doi">10.24875/rmo.m19000078</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Braquiterapia ocular en el tratamiento del retinoblastoma. Experiencia en el Hospital Infantil de México]]></article-title>
<article-title xml:lang="en"><![CDATA[Ocular brachytherapy in the treatment of retinoblastoma. Experience in the Hospital Infantil de México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Patiño]]></surname>
<given-names><![CDATA[Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barnoya-Pérez de Engel]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Molina]]></surname>
<given-names><![CDATA[Norma C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Villanueva]]></surname>
<given-names><![CDATA[Heynar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Ortiz]]></surname>
<given-names><![CDATA[Marco A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Servicio de Oftalmología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Herrera Llerandi Servicio de Oncología Ocular ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Servicio de Radioterapia ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>93</volume>
<numero>4</numero>
<fpage>194</fpage>
<lpage>199</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2604-12272019000400194&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2604-12272019000400194&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2604-12272019000400194&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Describir los resultados del tratamiento con braquiterapia ocular en ojos únicos en pacientes con retinoblastoma (Rb) bilateral, así como las complicaciones de su uso como tratamiento primario o secundario.  Métodos: Serie de casos donde se identificaron todos los pacientes con Rb en el Hospital Infantil de México tratados con braquiterapia ocular con yodo-125 como salvamento ocular después del fallo en el control de la neoplasia mediante quimioterapia intravenosa, tratamiento focal con láser o crioterapia y radioterapia externa.  Resultados: Se incluyeron un total de siete pacientes, dos pacientes eran del sexo femenino, y cinco, de sexo masculino. Dos pacientes tenían Rb hereditario y seis eran bilaterales. Tres de los ojos tratados con braquiterapia eran derechos. El seguimiento promedio de estos pacientes fue de 5.35 años (rango 3.3 a 11 años). El éxito del tratamiento se alcanzó en cinco de los siete pacientes. Dos pacientes fueron enucleados a pesar del tratamiento con braquiterapia por falla en el control de la neoplasia. Uno de los pacientes falleció por neoplasia secundaria.  Conclusiones: El tratamiento con braquiterapia ocular en un hospital de tercer nivel ofrece posibilidades de preservación ocular en pacientes con Rb bilateral y tratamiento oncológico máximo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To describe results and complications of salvage eye treatment with brachytherapy in patients with diagnosis of bilateral retinoblastoma (Rb) and only one eye.  Methods: Case series where we included all retinoblastoma patients treated with ocular brachytherapy with Iodine-125 at the Hospital Infantil de Mexico after failure of eye salvage with intravenous chemotherapy, focal transpupillary laser o transconjunctival cryotherapy and external beam radiotherapy.  Results: We analyzed 7 patients, 2 females and 5 males. Two had hereditary retinoblastoma and all had bilateral disease. Mean follow-up after treatment was 5.35 years (range 3.3&#8211;11 years). Tumor control was achieved in five of seven patients; two patients undergone enucleation due to failure to achieve tumor control. One of the patients died because of secondary neoplasm.  Conclusions: Ocular brachytherapy treatment in a tertiary care center offers possibilities of ocular preservation in patients with bilateral Rb and maximum oncological treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Retinoblastoma]]></kwd>
<kwd lng="es"><![CDATA[Braquiterapia]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Ceguera adquirida]]></kwd>
<kwd lng="es"><![CDATA[Terapia de salvamento]]></kwd>
<kwd lng="en"><![CDATA[Retinoblastoma]]></kwd>
<kwd lng="en"><![CDATA[Brachytherapy]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Acquired blindness]]></kwd>
<kwd lng="en"><![CDATA[Salvage therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Ellsworth]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rozakis]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cryotherapy for retinoblastoma]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1982</year>
<volume>100</volume>
<page-range>1253-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Parsons]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Giblin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of photocoagulation in the management of retinoblastoma]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1990</year>
<volume>108</volume>
<page-range>205-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphree]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Villablanca]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Deegan 3rd]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Malogolowin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy plus local treatment in the management of intraocular retinoblastoma]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1996</year>
<volume>114</volume>
<page-range>1348-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Diniz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gunduz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cater]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thermotherapy for retinoblastoma]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1999</year>
<volume>117</volume>
<page-range>885-93</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toma]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Hungerford]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Plowman]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Kingston]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Doughty]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[External beam radiotherapy for retinoblastoma:II. Lens sparing technique]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>1995</year>
<volume>79</volume>
<page-range>112-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munier]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Verwey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pica]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balmer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zografos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abouzeid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New developments in external beam radiotherapy for retinoblastoma:from lens to normal tissue-sparing techniques]]></article-title>
<source><![CDATA[Clin Experiment Ophthalmol]]></source>
<year>2008</year>
<volume>36</volume>
<page-range>78-89</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munier]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Gaillard]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Balmer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soliman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Podilsky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Moulin]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Beck-Popovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited:from prohibition to conditional indications]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2012</year>
<volume>96</volume>
<page-range>1078-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Dunkel]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Gobin]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2008</year>
<volume>115</volume>
<page-range>1398-404</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Marr]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Dunkel]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Palioura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gobin]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma:Five year review]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2012</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Penn]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second neoplasms following radiotherapy or chemotherapy for cancer]]></article-title>
<source><![CDATA[Am J Clin Oncol]]></source>
<year>1982</year>
<volume>5</volume>
<page-range>83-96</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abramson]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second nonocular tumors in survivors of bilateral retinoblastoma:a possible age effect on radiation-related risk]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>1998</year>
<volume>105</volume>
<page-range>573-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Gould]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Hilton]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Galindo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haik]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Episcleral plaque brachytherapy for retinoblastoma]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2004</year>
<volume>43</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Wolden]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[McCormick]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Segal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2013</year>
<volume>87</volume>
<page-range>517-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphree]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraocular retinoblastoma:the case for a new group classification]]></article-title>
<source><![CDATA[Ophthalmol Clin North Am]]></source>
<year>2005</year>
<volume>18</volume>
<page-range>41-53</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>American Brachytherapy Society - Ophthalmic Oncology Task Force</collab>
<article-title xml:lang=""><![CDATA[The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma]]></article-title>
<source><![CDATA[Brachytherapy]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[De Potter]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plaque radiotherapy for residual or recurrent retinoblastoma in 91 cases]]></article-title>
<source><![CDATA[J Pediatr Ophthalmol Strabismus]]></source>
<year>1994</year>
<volume>31</volume>
<page-range>242-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Garway-Heath]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Love]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Plowman]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Kingston]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Hungerford]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship of regression pattern to recurrence in retinoblastoma]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>1993</year>
<volume>77</volume>
<page-range>12-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Stallard]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Milner]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retinal Gliomata Treated by Radon Seeds]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>1931</year>
<volume>15</volume>
<page-range>673-96</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stallard]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The conservative treatment of retinoblastoma]]></article-title>
<source><![CDATA[Trans Ophthalmol Soc U K]]></source>
<year>1962</year>
<volume>82</volume>
<page-range>473-534</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Mashayekhi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Uysal]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Friere]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Komarnicky]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2006</year>
<volume>113</volume>
<page-range>2087-92</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cater]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Othmane]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Micaily]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plaque radiotherapy for retinoblastoma:long term tumor control and treatment complications in 208 tumors]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2001</year>
<volume>108</volume>
<page-range>2116-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshimura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Inaba]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kuroda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[106 Ruthenium plaque therapy (RPT) for retinoblastoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2012</year>
<volume>84</volume>
<page-range>59-65</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[McGee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Billups]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Qaddoumi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bellerive]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiation Retinopathy 47 Years following Brachytherapy for Retinoblastoma]]></article-title>
<source><![CDATA[Ocul Oncol Pathol]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>157-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
